Hunter syndrome immune study halted before it began

NCT ID NCT05494593

First seen Jan 04, 2026 · Last updated May 17, 2026 · Updated 25 times

Summary

This study aimed to see if a special immune-suppressing regimen could prevent the body from making antibodies that block the main treatment for Hunter syndrome. It was designed for boys who had never received the enzyme therapy ELAPRASE. However, the study was withdrawn before any participants were enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUNTER SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Ann and Robert H Lurie Childrens Hospital of Chicago

    Chicago, Illinois, 60611, United States

  • Children's Hospital and Research Center at Oakland

    Oakland, California, 94609, United States

  • Children's Hospitals and Clinics of Minnesota

    Minneapolis, Minnesota, 55404, United States

  • NewYork-Presbyterian Morgan Stanley Children's Hospital

    New York, New York, 10032, United States

  • Phoenix Childrens Hospital

    Phoenix, Arizona, 85016, United States

  • Rady Childrens Hospital San Diego - PIN

    San Diego, California, 92123, United States

  • The Cleveland Clinic Foundation

    Twinsburg, Ohio, 44087, United States

  • The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Center

    Torrance, California, 90502, United States

Conditions

Explore the condition pages connected to this study.